Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac epolamine - IBSA

Next Previous
Drug Profile

Diclofenac epolamine - IBSA

Alternative Names: DHEP - IBSA; Diclofenac epolamine topical system 1.3% - Institut Biochemique SA; Diclofenac epolamine transdermal patch - Institut Biochemique SA; Diclofenac-N-(2-hydroxyethyl)-pyrrolidine - IBSA; Effigel; Flector EP Tissugel; Flector Patch; Flector Tissugel; Licart

Latest Information Update: 03 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IBSA
  • Class Analgesics; Aniline compounds; Antirheumatics; Benzene derivatives; Chlorinated hydrocarbons; Nonsteroidal anti-inflammatories; Phenylacetates; Pyrrolidines; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain; Pain
  • Phase III Soft tissue injuries

Most Recent Events

  • 03 Feb 2026 Phase III trials in Soft tissue injuries (In adolescents, In adults, In children)is underway in USA (Topical) (NCT05171673)
  • 03 Feb 2026 No development reported - Phase-III for Acute pain (In the elderly, In adults) in Czech Republic, Poland (Topical) (IBSA website, February 2026)
  • 07 Jan 2026 Diclofenac epolamine (Licart®) licensed to Acertis Pharmaceuticals for commercialisation in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top